trending Market Intelligence /marketintelligence/en/news-insights/trending/8-q_vcb0bcdgcwktscwvnw2 content esgSubNav
In This List

Ascendis Pharma to sell $150M American depositary shares

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Ascendis Pharma to sell $150M American depositary shares

Ascendis Pharma A/S plans to sell $150 million of its American depositary shares, each representing 1 ordinary share of the company, in an underwritten public offering.

The company also plans to grant the underwriters an option to buy up to an additional $22.5 million of ADSs.

J.P. Morgan Securities LLC, Bank of America Merrill Lynch and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering.